NIH-sponsored Macrolide Azithromycin COPD Phase III Study Utilizes Med-ic(R) Smart Blister Packaging

Med-ic(R) ECM(R) technology records patient adherence and facilitates

intervention



06 Dec, 2005, 00:00 ET from INFORMATION MEDIARY CORP.

    OTTAWA, Dec. 6 /PRNewswire/ - Information Mediary Corporation has begun
 to supply over 30,000 of its Med-ic(R) RFID smart sensor labels for use in a
 large multi-year COPD Macrolide study. The study, sponsored by NIH's National
 Heart, Lung, and Blood Institute (NHLBI) will be enrolling over 1100 patients
 with moderate-to-severe chronic obstructive pulmonary disease (COPD), with
 emphasis on the prevention and management of exacerbations of the disease.
     "With 17 study sites managed by 10 universities throughout the United
 States, the Med-ic ECM smart pharmaceutical blister technology
 (www.med-ic.biz) allows for immediate intervention upon patient visits, while
 the recorded adherence data will be an invaluable information source during
 the biostatistical evaluation of the trials outcome involving nearly half a
 million individual doses of medication" states Prof. Allan Wilson, MD, PhD,
 President of smart packaging experts Information Mediary Corp.
 
     About Med-ic(R):
 
     The Med-ic ECM (Electronic Compliance Monitor) is a revolutionary RFID
 sensor device that provides a disposable, inexpensive, state-of-the-art method
 to address the multi-billion dollar health care problem of medication non-
 compliance. Med-ic's unique patent-pending design makes it very easy to
 integrate and supply in large volumes at a reasonable unit cost.
     Using intelligent technologies and advanced engineering, Information
 Mediary Corp. developed the Med-ic ECM to track medication usage for any
 standard blister packaging format without active patient input. The Med-ic ECM
 solution uses patent-pending sensor grid technology and a proprietary process
 of printed conductive inks from XINK Laboratories Ltd. (www.xink.biz) to form
 a smart paper label inlay.
     The Med-ic CertiScan(R) RF Reader and CertiScan Compliance Monitoring
 Software (www.certiscan.biz) retrieve and display patient compliance
 information using the latest in RFID technology.
 
     Study Background:
 
     This Macrolide Azithromycin COPD Phase III study is currently enrolling
 patients at Denver City-County Health/Hospitals Department; University of
 Alabama, Birmingham; Harbor-UCLA Research & Education Institute; University of
 Minnesota Twin Cities; Temple University; University of California at San
 Francisco; University of Michigan; Minnesota Veterans Research Institute;
 Brigham and Women's Hospital; University of Maryland; and University of
 Pittsburgh.
     Chronic obstructive pulmonary disease (COPD) is a serious public health
 problem that is responsible for more than 500,000 hospitalizations,
 100,000 deaths, and $15 billion in direct costs of medical care in the U.S.
 each year. In addition, millions of Americans are disabled by this disease.
 While smoking cessation is of clear benefit in slowing the progressive loss of
 lung function that is characteristic of COPD, management of established
 disease is largely limited to supportive measures that do not interfere with
 the disease process itself. More effective management strategies are needed.
 There is particular need for better prevention and management of exacerbations
 of COPD since these are associated with a substantial portion of the
 hospitalizations, deaths, and costs of care attributable to the disease. While
 certain supportive measures (such as long term oxygen therapy) are of
 established benefit in selected patients, there remains considerable
 uncertainty regarding the effectiveness of many treatment modalities that are
 routinely used in COPD, indications for specific therapies, the usefulness of
 novel therapeutic approaches, and the best means for management of common
 comorbid conditions.
 
     About Information Mediary Corporation:
 
     Information Mediary Corporation offers custom designed RFID sensors
 (Class 3 EPC RFID tags), RFID readers, and groundbreaking innovations in
 printed electronics. IMC has developed affordable, low cost wireless cold
 chain temperature sensors, and smart label inlays that can monitor patient
 adherence with prescribed medication dispensed from intelligent pharmaceutical
 packages. For a detailed presentation about this technology, please refer to
 IMC's Intelligent Active Consumer Packaging Presentation.
 
 

SOURCE INFORMATION MEDIARY CORP.
    OTTAWA, Dec. 6 /PRNewswire/ - Information Mediary Corporation has begun
 to supply over 30,000 of its Med-ic(R) RFID smart sensor labels for use in a
 large multi-year COPD Macrolide study. The study, sponsored by NIH's National
 Heart, Lung, and Blood Institute (NHLBI) will be enrolling over 1100 patients
 with moderate-to-severe chronic obstructive pulmonary disease (COPD), with
 emphasis on the prevention and management of exacerbations of the disease.
     "With 17 study sites managed by 10 universities throughout the United
 States, the Med-ic ECM smart pharmaceutical blister technology
 (www.med-ic.biz) allows for immediate intervention upon patient visits, while
 the recorded adherence data will be an invaluable information source during
 the biostatistical evaluation of the trials outcome involving nearly half a
 million individual doses of medication" states Prof. Allan Wilson, MD, PhD,
 President of smart packaging experts Information Mediary Corp.
 
     About Med-ic(R):
 
     The Med-ic ECM (Electronic Compliance Monitor) is a revolutionary RFID
 sensor device that provides a disposable, inexpensive, state-of-the-art method
 to address the multi-billion dollar health care problem of medication non-
 compliance. Med-ic's unique patent-pending design makes it very easy to
 integrate and supply in large volumes at a reasonable unit cost.
     Using intelligent technologies and advanced engineering, Information
 Mediary Corp. developed the Med-ic ECM to track medication usage for any
 standard blister packaging format without active patient input. The Med-ic ECM
 solution uses patent-pending sensor grid technology and a proprietary process
 of printed conductive inks from XINK Laboratories Ltd. (www.xink.biz) to form
 a smart paper label inlay.
     The Med-ic CertiScan(R) RF Reader and CertiScan Compliance Monitoring
 Software (www.certiscan.biz) retrieve and display patient compliance
 information using the latest in RFID technology.
 
     Study Background:
 
     This Macrolide Azithromycin COPD Phase III study is currently enrolling
 patients at Denver City-County Health/Hospitals Department; University of
 Alabama, Birmingham; Harbor-UCLA Research & Education Institute; University of
 Minnesota Twin Cities; Temple University; University of California at San
 Francisco; University of Michigan; Minnesota Veterans Research Institute;
 Brigham and Women's Hospital; University of Maryland; and University of
 Pittsburgh.
     Chronic obstructive pulmonary disease (COPD) is a serious public health
 problem that is responsible for more than 500,000 hospitalizations,
 100,000 deaths, and $15 billion in direct costs of medical care in the U.S.
 each year. In addition, millions of Americans are disabled by this disease.
 While smoking cessation is of clear benefit in slowing the progressive loss of
 lung function that is characteristic of COPD, management of established
 disease is largely limited to supportive measures that do not interfere with
 the disease process itself. More effective management strategies are needed.
 There is particular need for better prevention and management of exacerbations
 of COPD since these are associated with a substantial portion of the
 hospitalizations, deaths, and costs of care attributable to the disease. While
 certain supportive measures (such as long term oxygen therapy) are of
 established benefit in selected patients, there remains considerable
 uncertainty regarding the effectiveness of many treatment modalities that are
 routinely used in COPD, indications for specific therapies, the usefulness of
 novel therapeutic approaches, and the best means for management of common
 comorbid conditions.
 
     About Information Mediary Corporation:
 
     Information Mediary Corporation offers custom designed RFID sensors
 (Class 3 EPC RFID tags), RFID readers, and groundbreaking innovations in
 printed electronics. IMC has developed affordable, low cost wireless cold
 chain temperature sensors, and smart label inlays that can monitor patient
 adherence with prescribed medication dispensed from intelligent pharmaceutical
 packages. For a detailed presentation about this technology, please refer to
 IMC's Intelligent Active Consumer Packaging Presentation.
 
 SOURCE  INFORMATION MEDIARY CORP.